Jan. 28, 2021: COVID-19 information mistrust among Black PLWH; opportunities to intervene prior to deadly drug overdoses; we're unprepared for end-of-life needs for aging PLWH; hospitalization disparities despite universal health care.
Jan. 21, 2021: Dyad-level interventions in serodiscordant relationships; using social media to improve PrEP uptake; HCV prevalence among MSM; the irrelevance of doxycycline prophylaxis against mycoplasma genitalium.
HIV infection rates among Black women in the U.S. have fallen sharply over the past decade, but look closer and the numbers still paint a troubling story.
B/F/TAF Holds Up as Switch Regimen for Black People Living With HIV, Including Those With Resistance
While the most striking aspect of the study was its demographic focus, the baseline resistance profile of the participants was also key.
Oct. 15, 2020: Adherence barriers among Latinx MSM; Atlanta's Ending the HIV Epidemic priorities; Ryan White HIV service coordination; PrEP, white coat dosing, and drug resistance.
Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.
Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
This Champion of Community’s Role in Clinical Trials Reflects on 40 Years of Fighting Medical Mistrust And Research Neglect
Wakefield retires from the HIV Vaccine Trials Network after 20 years of service.
July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.